JAZZ Earnings Date: Nov 2, 2026 (Estimated) — Jazz Pharmaceuticals plc
NASDAQ · Healthcare · Biotechnology
Updated
When is JAZZ's next earnings date?
Jazz Pharmaceuticals plc (JAZZ) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$4.05 on revenue of $1.21B.
How did JAZZ do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), Jazz Pharmaceuticals plc posted EPS of $5.71 versus the $5.94 estimate, a miss of 3.9%. Revenue was $1.21B against a $1.11B estimate. The stock's 1-day post-earnings move was +4.0%.
How much does JAZZ stock move after earnings?
JAZZ beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.2% (up or down) in the day after earnings.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | 5.94 | 5.71 | -3.87% | $1.21B | ❌ Miss | +3.99% | +1.96% | -3.13% |
| 2026-05-05 | Q1 2026 | 4.49 | 6.34 | +41.20% | $1.61B | ✅ Beat | +7.68% | +7.34% | +13.10% |
| 2026-02-24 | Q4 2025 | 6.16 | 6.64 | +7.79% | $1.20B | ✅ Beat | +13.23% | +7.39% | +8.77% |
| 2025-11-05 | Q3 2025 | 5.43 | 8.13 | +49.72% | $1.13B | ✅ Beat | -2.31% | -0.37% | +23.67% |
| 2025-08-05 | Q2 2025 | -6.34 | -8.25 | -30.13% | $1.05B | ❌ Miss | -6.42% | +0.11% | +13.09% |
| 2025-02-25 | Q4 2024 | 5.81 | 6.60 | +13.60% | $1.09B | ✅ Beat | +3.22% | -0.52% | -6.29% |
| 2024-07-31 | Q2 2024 | 4.80 | 5.30 | +10.42% | $1.02B | ✅ Beat | +3.75% | +1.81% | +4.85% |
| 2024-05-01 | Q1 2024 | 4.18 | 2.68 | -35.89% | $902.0M | ❌ Miss | -0.92% | +0.35% | -4.59% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.16B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Xywav | 40.6% | $471.2M | +13.5% | $401.0M | $344.8M | $415.3M | $431.4M |
| Epidiolex/Epidyolex | 25.2% | $292.1M | +16.0% | $275.0M | $217.7M | $251.7M | $302.6M |
| Zepzelca | 9.1% | $105.8M | +41.9% | $78.3M | $63.0M | $74.5M | $79.3M |
| Rylaze/Enrylaze | 8.6% | $99.5M | -1.2% | $101.5M | $94.2M | $100.7M | $99.9M |
| Defitelio/Defibrotide | 5.3% | $62.0M | +28.9% | $57.6M | $40.7M | $48.1M | $51.8M |
| High Sodium AG Oxybate Product Royalty Revenue | 3.6% | $42.2M | -22.1% | $55.3M | $48.9M | $54.1M | $52.9M |
| Vyxeos | 2.7% | $31.4M | -30.0% | $53.2M | $29.5M | $44.9M | $37.6M |
By region
Q2 FY26 · $1.21B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 89.2% | $1.08B | +15.1% | $973.6M | $797.9M | $936.3M | $1.02B |
| Europe | 8.1% | $97.4M | +17.7% | $81.9M | $83.6M | $82.8M | $86.4M |
| Other Countries | 2.7% | $33.0M | +23.8% | $32.7M | $16.3M | $26.7M | $19.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.